Gantz, Ira

Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein

Ollmann, M. M., Wilson, B. D., Yang, Y.-K., Kerns, J. A., Chen, Y., Gantz, I., & Barsh, G. S. (1997) · Science

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 1,881

Cardiovascular outcomes with ertugliflozin in type 2 diabetes

Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 1,514

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 1,235

Anatomy of an Endogenous Antagonist: Relationship between Agouti-Related Protein and Proopiomelanocortin in Brain

Bagnol, D., Lu, X.-Y., Kaelin, C. B., Day, H. E. W., Ollmann, M., Gantz, I., Akil, H., Barsh, G. S., & Watson, S. J. (1999) · The Journal of Neuroscience

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 425

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 242

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 163

Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,

Pogozheva, I. D., Chai, B.-X., Lomize, A. L., Fong, T. M., Weinberg, D. H., Nargund, R. P., Mulholland, M. W., Gantz, I., & Mosberg, H. I. (2005) · Biochemistry

Receptor Mechanisms and SignalingNeuropeptides and Animal Physiology

Cited by 92

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Dagogo-Jack, S., Pratley, R. E., Cherney, D. Z. I., McGuire, D. K., Cosentino, F., Shih, W. J., Liu, J., Frederich, R., Mancuso, J. P., Raji, A., et al. (2021) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 37